Programmed Death Ligand 1 (PD-L1) positive neutrophils play a key role in combatting bacterial infection and resolving infection-associated inflammation [33], and PD-L1 is a common pharmaceutical treatment target to blunt secondary colitis [34]. This evidence concerns the gene CD274 and colitis.